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Solitary small bowel metastasis secondary to lung cancer is very uncommon. In this report, we present a patient with NSCLC and a
metachronous solitary metastasis of the jejunum. She is alive without evidence of disease and doing well four years after palliative
surgery, radiotherapy, and chemotherapy. To the best of our knowledge, this is the ﬁrst case report describing a prolonged survival
in a patient with a symptomatic solitary small bowel metastasis treated with palliative surgery, chemo- and radiotherapy instead
of complete surgical resection.
1.Introduction
Lung cancer remains the leading cause of cancer-related
death in Western countries. Nonsmall cell lung cancer
(NSCLC) accounts for approximately 80% of these cases. At
the time of diagnosis of NSCLC, around 40% will have stage
IV disease with a median survival of 8–10 months and a 1-
year survival rate of 30% [1]. Treatment with chemotherapy
can be considered based on the performance status of these
patients.
In the literature, unusual presentations with prolonged
survival in patients with stage IV NSCLC are sporadically
described, dictating a diﬀerent therapeutic approach. For
instance, potentially curative surgery for solitary brain
metastasis or solitary adrenal gland metastasis has been
described [2]. Much less is known about therapeutic choices
incasesofanisolatedmetastasisinotherorgans.Anexample
of rare metastatic site of lung cancer is the small bowel.
Autopsy studies revealed small bowel metastases as the most
common gastrointestinal metastasis of NSCLC, with an inci-
dence of 4%, 6%–11% [3–6]. The number of clinical cases
reporting small bowel metastasis of NSCLC is underesti-
matedbecauseofconcurrentmetastaticsitesandthefactthat
most gastrointestinal metastases were asymptomatic (i.e.,
no dysphagia, abdominal pain, gastrointestinal bleeding,
obstruction, intussusceptions, or perforation) [3–6].
In this report, we present a case of NSCLC with a
metachronoussolitaryobstructivemetastasisinthejejunum.
The patient is still well and alive 4 years after subsequent
treatment with palliative surgery, palliative radio- and
chemotherapy. Moreover, a review of the literature on this
subject is given.
2.CaseReport
A 60-year-old woman, with a history of a superﬁcially inva-
sive urothelial cell carcinoma of the bladder, had undergone
a lung bilobectomy in January 2004 for a carcinoma in the
right upper lobe. At the time of diagnosis CT of the thorax
and F-18-ﬂuoro-positron emission tomography (FDG-PET)
showed no evidence of lymph node involvement or distant
metastases. Mediastinal lymph nodes were not sampled
during surgery. Histopathological evaluation of the resected
lung tissue revealed an undiﬀerentiated large cell carcinoma
of3,3cminthelungparenchymawithoutpleuralinvasionor
regional lymph node metastasis, T2N0M0 (Figure 1(a)). No
postoperative adjuvant treatment was recommended.
Eleven months later, the patient was referred again to
our hospital because of of abdominal pain, weight loss,
and fatigue. She had a performance score of 1. Physical
examination showed that a mass was palpable in the left2 Journal of Oncology
abdomen. Melena was not present at that time. All lymph
node regions were found normal on palpation. Laboratory
data showed no abnormalities.
A CT of the abdomen and double-balloon enteroscopy
showed a mass in the proximal jejunum (Figure 2). Double-
balloon enteroscopy, also known as push-enteroscopy, is an
endoscopic technique for visualization of the small bowel.
The technique involves the use of a balloon at the end of
a special enteroscope camera and an overtube, which is a
tube that ﬁts over the endoscope, and which also ﬁts with
the balloon. The enteroscope and overtube are inserted as a
regular gastroscope, into the small intestine. The endoscope
is advanced in front of the overtube and the balloon at the
endisinﬂated.Usingtheassistanceoffrictionattheinterface
of the enteroscope and intestinal wall, the small bowel is
accordioned back to the overtube. The overtube balloon is
then deployed, and the enteroscope balloon is deﬂated.
Biopsies of the jejunal mass showed groups of large
undiﬀerentiated cells in the lamina propria (Figure 1(b)).
Immunohistochemical analysis revealed the tumor cells to
be positive for TTF-1, cytokeratin8/ 18, cytokeratin 7,
and vimentin. This immunohistochemical proﬁle of the
metastatic mass appeared comparable with the proﬁle of
previous lung tumor. It was concluded that the jejunal
lesion was a metastasis of the primary lung carcinoma. This
was later substantiated by mutation analysis of these two
tumor tissue samples. Identical tumor-speciﬁc oncogenic K-
ras gene codon 61 mutation was found in the lung tumor as
wellasinthejejunalmetastasis.Theprimaryurinarybladder
carcinoma did not show this mutation.
Two days after the initial histopathological diagnosis
was made, intestinal obstruction occurred. Subsequent
laparotomy showed a large tumor in the jejunum, which
was adhered to the ﬂexura lienalis region. Due to inva-
sion of the mesothelium, tumor resection could not be
carried out. Instead, side-to-side duodenojejunostomy was
performed. Postoperatively, gastrointestinal bleeding with
melena occurred. Gastroscopy showed no abnormalities.
Palliative radiotherapy with a total dose of 15 GY in 5
fractions on the metastatic site was given after which the
bleeding did not recur. Follow-up CT of the abdomen after
2 months showed complete absence of residual tumor in the
jejunum (Figure 3).
Itwaschosentofurthertreatthepatientwithchemother-
apy consisting of cisplatin 80mg/m2 and vinorelbine
30mg/m2 in a 3-week cycle. In total, she received 3 cycles.
Chemotherapy was then cancelled because of serious side
eﬀects (i.e., hearing loss, presumably due to the platinum
derivate).
On follow up, the patient is doing well without any
evidence of disease, 4 years after being diagnosed with a
solitary metastasis of NSCLC in the jejunum.
3. Discussion
To the best of our knowledge, this is the ﬁrst case report
describing-prolonged survival in a patient with NSCLC and
a symptomatic metachronous solitary small bowel metas-
(a)
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Figure 1: Microscopic images of the primary lung cancer and
jejunal metastasis. H&E, 250X. (a), lung: a nest of large, poly-
morphous epithelial cells with strong mitotic activity and central
necrosis is observed, consistent with large cell carcinoma (NSCLC).
(b), jejunum: groups of large anaplastic cells invading the lamina
propria.
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Figure 2: CT of the abdomen showing a solitary circular mass in
the small bowel with surrounding fat inﬁltration.
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Figure 3:CToftheabdomen2monthsafterpalliativeradiotherapy
showing absence of residual tumor in the jejunum.Journal of Oncology 3
tasis treated with palliative surgery and palliative chemo-
and radiotherapy instead of complete surgical resection.
Rossi et al. described two patients with NSCLC and syn-
chronous solitary small bowel metastasis who underwent
small bowel resection, subsequent pulmonary lobectomy,
and chemotherapy and are alive without evidence of disease
[7].
As o l i t a r ys m a l lb o w e lm e t a s t a s i so fN S C L Ci sv e r y
uncommon. The jejunum seems to be the most common
gastrointestinal site in these cases. The biology of a single
metastatic site in patients with lung cancer remains unclear.
No predominant histological cancer subtype has been char-
acterized [4–6].
Screening for gastrointestinal metastases using CT of the
abdomen has a low sensitivity. The use of whole-body FDG-
PET for staging of lung cancer might increase the detection
ofsmallbowelmetastases.Recently,tworetrospectivestudies
discuss the usefulness of FDG-PET in detecting gastroin-
testinal metastases in patients diagnosed with lung cancer
[8, 9]. These studies showed that FDG-PET imaging might
have a role in the detection of gastro intestinal metastases.
From these limited data, no conclusions on the sensitivity of
FDG-PET for establishment of small bowel metastases can
be drawn. Also in the described patient retrospectively the
metastatic side could not be established after reviewing the
FDG-PET.
Little can be said about survival period in patients with
solitary small bowel metastasis of NSCLC as no ﬁrm data on
this subject are available. Most patients described in the liter-
ature underwent surgical resection of the small bowel mass
because of life-threatening complications and many times
multiplemetastaticsiteswereinvolved.AreviewbyGarwood
et al. describing cases with bowel perforation secondary to
metastatic NSCLC showed a mean survival of 66 days [10].
Only few case reports describe small bowel localization as
the unique site of metastasized NSCLC [7, 11–15]. Goh et
al. reported a case series of 8 patients presenting with acute
complications of gastrointestinal metastases from NSCLC
[15]. Four of eight patients had a solitary metachronous
metastasis small bowel. After resection of the metastasis, all
four lived longer than six months.
The choice of chemotherapy in our case remains
arbitrary. Due to earlier palliative radiotherapy, residual
metastatic tumor in the jejunum was not detectable any-
more.Therefore, the eﬀectiveness of chemotherapy could
not be determined. It might have been solely the eﬀect
of radiotherapy on the metastatic mass that resulted in
p r o l o n g e ds u r v i v a lo fo u rp a t i e n t .
4. Conclusion
As m a l lb o w e lm e t a s t a s i ss e c o n d a r yt oN S C L Ci sp r o b a b l y
more frequent than expected, and physicians should always
keep in mind this possibility. The rarity of solitary small
bowel metastasis makes it diﬃcult, if not impossible, to
analyze these patient groups in randomized controlled
trials. Without evidence-based medicine, an individualized
approach is important.
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